Cargando…

CNPase, a 2′,3′-Cyclic-nucleotide 3′-phosphodiesterase, as a Therapeutic Target to Attenuate Cardiac Hypertrophy by Enhancing Mitochondrial Energy Production

Heart failure is the end-stage of all cardiovascular diseases with a ~25% 5-year survival rate, and insufficient mitochondrial energy production to meet myocardial demand is the hallmark of heart failure. Mitochondrial components involved in the regulation of ATP production remain to be fully elucid...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Keai Sinn, Wang, Dongfang, Lu, Ziqiang, Zhang, Yihan, Li, Sixu, Lin, Yue, Tan, Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509266/
https://www.ncbi.nlm.nih.gov/pubmed/34639145
http://dx.doi.org/10.3390/ijms221910806
_version_ 1784582296795348992
author Tan, Keai Sinn
Wang, Dongfang
Lu, Ziqiang
Zhang, Yihan
Li, Sixu
Lin, Yue
Tan, Wen
author_facet Tan, Keai Sinn
Wang, Dongfang
Lu, Ziqiang
Zhang, Yihan
Li, Sixu
Lin, Yue
Tan, Wen
author_sort Tan, Keai Sinn
collection PubMed
description Heart failure is the end-stage of all cardiovascular diseases with a ~25% 5-year survival rate, and insufficient mitochondrial energy production to meet myocardial demand is the hallmark of heart failure. Mitochondrial components involved in the regulation of ATP production remain to be fully elucidated. Recently, roles of 2′,3′-cyclic nucleotide-3′-phosphodiesterase (CNPase) in the pathophysiological processes of heart diseases have emerged, implicated by evidence that mitochondrial CNPase proteins are associated with mitochondrial integrity under metabolic stress. In this study, a zebrafish heart failure model was established, by employing antisense morpholino oligonucleotides and the CRISPR-Cas9 gene-editing system, which recapitulates heart failure phenotypes including heart dysfunction, pericardial edema, ventricular enlargement, bradycardia, and premature death. The translational implications of CNPase in the pathophysiological process of heart failure were tested in a pressure overload-induced heart hypertrophy model, which was carried out in rats through transverse abdominal aorta constriction (TAAC). AAV9-mediated myocardial delivery of CNPase mitigated the hypertrophic response through the specific hydrolysis of 2′-3′-cyclic nucleotides, supported by the decrease of cardiac hypertrophy and fibrosis, the integrity of mitochondrial ultrastructure, and indicators of heart contractility in the AAV9-TAAC group. Finally, the biometrics of a mitochondrial respiration assay carried out on a Seahorse cellular energy analyzer demonstrated that CNPase protects mitochondrial respiration and ATP production from AngII-induced metabolic stress. In summary, this study provides mechanistic insights into CNPase-2′,3′-cyclic nucleotide metabolism that protects the heart from energy starvation and suggests novel therapeutic approaches to treat heart failure by targeting CNPase activity.
format Online
Article
Text
id pubmed-8509266
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85092662021-10-13 CNPase, a 2′,3′-Cyclic-nucleotide 3′-phosphodiesterase, as a Therapeutic Target to Attenuate Cardiac Hypertrophy by Enhancing Mitochondrial Energy Production Tan, Keai Sinn Wang, Dongfang Lu, Ziqiang Zhang, Yihan Li, Sixu Lin, Yue Tan, Wen Int J Mol Sci Communication Heart failure is the end-stage of all cardiovascular diseases with a ~25% 5-year survival rate, and insufficient mitochondrial energy production to meet myocardial demand is the hallmark of heart failure. Mitochondrial components involved in the regulation of ATP production remain to be fully elucidated. Recently, roles of 2′,3′-cyclic nucleotide-3′-phosphodiesterase (CNPase) in the pathophysiological processes of heart diseases have emerged, implicated by evidence that mitochondrial CNPase proteins are associated with mitochondrial integrity under metabolic stress. In this study, a zebrafish heart failure model was established, by employing antisense morpholino oligonucleotides and the CRISPR-Cas9 gene-editing system, which recapitulates heart failure phenotypes including heart dysfunction, pericardial edema, ventricular enlargement, bradycardia, and premature death. The translational implications of CNPase in the pathophysiological process of heart failure were tested in a pressure overload-induced heart hypertrophy model, which was carried out in rats through transverse abdominal aorta constriction (TAAC). AAV9-mediated myocardial delivery of CNPase mitigated the hypertrophic response through the specific hydrolysis of 2′-3′-cyclic nucleotides, supported by the decrease of cardiac hypertrophy and fibrosis, the integrity of mitochondrial ultrastructure, and indicators of heart contractility in the AAV9-TAAC group. Finally, the biometrics of a mitochondrial respiration assay carried out on a Seahorse cellular energy analyzer demonstrated that CNPase protects mitochondrial respiration and ATP production from AngII-induced metabolic stress. In summary, this study provides mechanistic insights into CNPase-2′,3′-cyclic nucleotide metabolism that protects the heart from energy starvation and suggests novel therapeutic approaches to treat heart failure by targeting CNPase activity. MDPI 2021-10-06 /pmc/articles/PMC8509266/ /pubmed/34639145 http://dx.doi.org/10.3390/ijms221910806 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Tan, Keai Sinn
Wang, Dongfang
Lu, Ziqiang
Zhang, Yihan
Li, Sixu
Lin, Yue
Tan, Wen
CNPase, a 2′,3′-Cyclic-nucleotide 3′-phosphodiesterase, as a Therapeutic Target to Attenuate Cardiac Hypertrophy by Enhancing Mitochondrial Energy Production
title CNPase, a 2′,3′-Cyclic-nucleotide 3′-phosphodiesterase, as a Therapeutic Target to Attenuate Cardiac Hypertrophy by Enhancing Mitochondrial Energy Production
title_full CNPase, a 2′,3′-Cyclic-nucleotide 3′-phosphodiesterase, as a Therapeutic Target to Attenuate Cardiac Hypertrophy by Enhancing Mitochondrial Energy Production
title_fullStr CNPase, a 2′,3′-Cyclic-nucleotide 3′-phosphodiesterase, as a Therapeutic Target to Attenuate Cardiac Hypertrophy by Enhancing Mitochondrial Energy Production
title_full_unstemmed CNPase, a 2′,3′-Cyclic-nucleotide 3′-phosphodiesterase, as a Therapeutic Target to Attenuate Cardiac Hypertrophy by Enhancing Mitochondrial Energy Production
title_short CNPase, a 2′,3′-Cyclic-nucleotide 3′-phosphodiesterase, as a Therapeutic Target to Attenuate Cardiac Hypertrophy by Enhancing Mitochondrial Energy Production
title_sort cnpase, a 2′,3′-cyclic-nucleotide 3′-phosphodiesterase, as a therapeutic target to attenuate cardiac hypertrophy by enhancing mitochondrial energy production
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509266/
https://www.ncbi.nlm.nih.gov/pubmed/34639145
http://dx.doi.org/10.3390/ijms221910806
work_keys_str_mv AT tankeaisinn cnpasea23cyclicnucleotide3phosphodiesteraseasatherapeutictargettoattenuatecardiachypertrophybyenhancingmitochondrialenergyproduction
AT wangdongfang cnpasea23cyclicnucleotide3phosphodiesteraseasatherapeutictargettoattenuatecardiachypertrophybyenhancingmitochondrialenergyproduction
AT luziqiang cnpasea23cyclicnucleotide3phosphodiesteraseasatherapeutictargettoattenuatecardiachypertrophybyenhancingmitochondrialenergyproduction
AT zhangyihan cnpasea23cyclicnucleotide3phosphodiesteraseasatherapeutictargettoattenuatecardiachypertrophybyenhancingmitochondrialenergyproduction
AT lisixu cnpasea23cyclicnucleotide3phosphodiesteraseasatherapeutictargettoattenuatecardiachypertrophybyenhancingmitochondrialenergyproduction
AT linyue cnpasea23cyclicnucleotide3phosphodiesteraseasatherapeutictargettoattenuatecardiachypertrophybyenhancingmitochondrialenergyproduction
AT tanwen cnpasea23cyclicnucleotide3phosphodiesteraseasatherapeutictargettoattenuatecardiachypertrophybyenhancingmitochondrialenergyproduction